BPMC - Blueprint Medicines Corp
IEX Last Trade
90.38
1.080 1.195%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:57 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$89.30
1.08
1.21%
Fundamental analysis
9%
Profitability
0%
Dept financing
18%
Liquidity
67%
Performance
1%
Performance
5 Days
0.36%
1 Month
-3.63%
3 Months
3.98%
6 Months
-15.10%
1 Year
1.83%
2 Year
104.89%
Key data
Stock price
$90.38
DAY RANGE
$89.30 - $90.76
52 WEEK RANGE
$75.71 - $121.90
52 WEEK CHANGE
-$2.56
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/24/2024
Company detail
CEO: Kathryn Haviland
Region: US
Website: blueprintmedicines.com
Employees: 640
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: blueprintmedicines.com
Employees: 640
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Blueprint Medicines Corporation develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor, is developing Fisogatinib.
Recent news